Anti-Human cMyc (Clone 9E10) – FITC

Anti-Human cMyc (Clone 9E10) – FITC

Product No.: C592

- -
- -
Clone
9E10
Target
c-Myc
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
myc tag, c-Myc tag, Myc epitope tag
Isotype
Mouse IgG1 κ
Applications
ELISA
,
FC
,
IF
,
IHC
,
IP
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Epitope Tag
Host Species
Mouse
Immunogen
C-terminal region of human c-myc
Product Concentration
0.2 mg/ml
Formulation
This Fluorescein (FITC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
State of Matter
Liquid
Storage and Handling
This Fluorescein conjugate is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Excitation Laser
Blue Laser (488 nm)
Additional Applications Reported In Literature ?
IHC,
IP,
IF,
WB,
ELISA,
FC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
9E10 activity is directed against human c-Myc and can cross-react with denatured murine c-Myc in some circumstances.
Antigen Distribution
c-Myc is ubiquitously expressed during tissue development and in a wide variety of tumors. c-Myc is often studied in embryonic stem cells and induced pluripotent stem cells. c-Myc is mainly associated with cell nuclei.
Background
c-Myc is an essential transcription factor that belongs to the superfamily of basic helix-loop- helix DNA-binding proteins that function in normal embryogenesis, acquisition and maintenance of stem cell properties, metabolism, cellular division, and cell death1, 2. c-Myc is also a proto-oncogene, originally identified in Burkitt lymphoma1. Its dysregulation, by mutation or epigenetic modification, has been observed in over 50% of human cancers3. c-Myc regulates various cancer cellular functions, including cell cycle, survival, proliferation, and metabolic reprogramming1, and is associated with tumor aggression and chemoresistance3. c-Myc has been suggested as a target for cancer immunotherapy 2and various methods of inhibition have been studied1, 2, 3.

9E10 was generated by immunizing a BALB/c mouse with a synthetic peptide corresponding to residues 408-432 of human c-Myc conjugated to keyhole limpet hemocyanin via the cysteine residues4. Splenocytes were fused with SP2 myeloma cells. 9E10 failed to immunoprecipitate protein from Colo 320 HSR cell extracts during screening but did detect c-Myc in Western blotting. The 9E10 epitope has become a well-known affinity tag used in recombinant protein expression, i.e., the myc-tag5. The target epitope is the C terminal EQKLISEEDL peptide with the core sequence being LISE5and the crystal structure and binding mode have been solved6. 9E10 detection has highly variable epitope recognition that is dependent on neighboring sequence context7. Additionally, cross-reactivity of 9E10 has been observed in murine cell lines in a fluorescence assay and by Western blotting8.

Antigen Details

NCBI Gene Bank ID
UniProt.org
Research Area
Cell Biology
.
Epitope Tag

References & Citations

1 Yoshida GJ. J Exp Clin Cancer Res. Jul 27;37(1):173. 2018.
2 Llombart V, Mansour MR. EBioMedicine. 75:103756. 2022.
3 Fatma H, Maurya SK, Siddique HR. Semin Cancer Biol. 83:166-176. 2022.
4 Evan GI, Lewis GK, Ramsay G, et al. Mol Cell Biol. 5(12):3610-3616. 1985.
5 Hilpert K, Hansen G, Wessner H, et al. Protein Eng. 14(10):803-806. 2001.
6 Krauss N, Wessner H, Welfle K, et al. Proteins. 73(3):552-565. 2008.
7 Schüchner S, Behm C, Mudrak I, et al. Sci Signal. 28;13(616):eaax9730. 2020.
8 Siegel J, Brandner G, Hess RD. Int J Oncol. 13(6):1259-1262. 1998.
9 Varughese M, Chi A, Teixeira AV, et al. Mol Med. 4(2):87-95. 1998.
10 Fan H, Villegas C, Chan AK, et al. Biochem Cell Biol. 76(1):125-128. 1998.
11 Chan S, Gabra H, Hill F, et al. Mol Cell Probes. 1(1):73-82. 1987.
12 Porter MJ, Field JK, Leung SF, et al. Acta Otolaryngol. 114(1):105-109. 1994.
13 O'Leary JJ, Landers RJ, Crowley M, et al. J Clin Pathol. 50(11):896-903. 1997.
14 Feller K, Yang S, Tung N, et al. J Eur Acad Dermatol Venereol. 28(1):120-124. 2014.
15 Baker AM, Van Noorden S, Rodriguez-Justo M, et al. Histopathology. 69(2):222-229. 2016.
Indirect Elisa Protocol
Flow Cytometry
IF
IHC
Immunoprecipitation Protocol
General Western Blot Protocol

Formats Available

- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.